他莫西芬与子宫内膜癌——关于他莫西芬治疗的乳腺癌患者发生子宫内膜癌的回顾性研究  

A Retrospective Study of Endometrial Carcinoma in Tamoxifen treated Breast Cancer Patients

作　　者：张伟华[1,2] 安达勇[1,2] 

机构地区：[1]甘肃省肿瘤医院内科 [2]日本国立癌中心中央病院内科

出　　处：《中国肿瘤临床》1998年第9期637-641,共5页Chinese Journal of Clinical Oncology

摘　　要：研究他莫西芬（Ｔａｍｏｘｉｆｅｎ，ＴＡＭ）治疗乳腺癌而发生子宫内膜癌的危险性及其病理特征。根据统计中心提供资料，查阅病历确认日本国立癌中心中央病院自１９６２年５月开院至１９９５年１２月间收治的２５例发生于乳腺癌后的子宫内膜癌病例。２５例中１３例因乳腺癌接受过ＴＡＭ治疗。１９９０年前２５年间仅发生９例，占同期收治子宫内膜癌总数的２．１％，而１９９０年后的５年中发生１６例，占同期收治的子宫内膜癌总数的７％，其中１３例接受过ＴＡＭ治疗。ＴＡＭ组中组织学８４．６％属低度恶性（ｇｒａｄｅ１～２），与非ＴＡＭ组中８３．３％相近。闭经后或有恶性肿瘤家族史者易受ＴＡＭ作用发生子宫内膜癌。ＴＡＭ增加了子宫内膜癌的发病危险。A retrospective study of risk and histologic features of endometrial carcinoma in patients with a history of breast cancer was done to investigate the effects of Tamoxifen (TAM).Twenty five cases of endometrial carcinoma developed in TAM treated breast cancer patients were identified by investigating case records.Thirteen of the 25 cases had prior TAM therapy,12 had none. There were only 9 cases which accounted for 2.1% of the total endometerial carcinoma cases treated in the hospital during a 25 years period of time before 1990. 84.6% of the cases in the TAM group were of low grade (grade 1 2)endometrioid adenocarcinoma, similar to that in the non TAM group. Postmenopausal patients or those who had a family history of malignant tumors were readily more predisposed to develop endometrial carcinoma under the affect of TAM. TAM increased the risk of endometrial carcinoma. There were no significant differences of the histologic type and grade between TAM group and non TAM group.

关 键 词：乳腺癌 他莫西芬 子宫内膜癌 药物疗法 

分 类 号：R737.905[医药卫生—肿瘤] R977.12[医药卫生—临床医学]